Altimmune Inc

NASDAQ:ALTUnited States

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Contact Information

Headquarters

910 Clopper Road, Suite 201SGAITHERSBURG, MD, United States 20878-1361

Phone

240-654-1450

Fax

302-674-5266

Executives

Independent Chairman of the Board

Mitchel Sayare

President, Chief Executive Officer, Director

Vipin Garg

Acting Chief Financial Officer

Andrew Shutterly

Chief Scientific Officer

M. Scot Roberts

Chief Medical Officer

M. Scott Harris